Advertisement
U.S. markets closed

CorMedix Inc. (CRMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.2400+0.0800 (+1.92%)
At close: 04:00PM EDT
4.2400 0.00 (0.00%)
After hours: 04:21PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.1600
Open4.1700
Bid4.2200 x 200
Ask4.2500 x 100
Day's Range4.1700 - 4.2550
52 Week Range2.5700 - 6.0900
Volume339,818
Avg. Volume437,929
Market Cap233.12M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-0.9100
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CRMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CorMedix Inc.
    Technical Assessment: Neutral in the Intermediate-TermWas that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.
    Rating
    Fair Value
    Economic Moat
    12 hours agoArgus Research
View more
  • GlobeNewswire

    CorMedix Inc. to Present at the Needham Annual Healthcare Conference

    BERKELEY HEIGHTS, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the Needham 23rd Annual Healthcare Conference, being held virtually on April 8 – 11, 2024. Needham 23rd Annual Healthcare Conference Date: Monda

  • GuruFocus.com

    Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities for DefenCath

    Net Loss Widens in Q4 and Full Year 2023; Company Prepares for Commercial Launch

  • GlobeNewswire

    CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its business. Recent Corporate Highlights: On November 15, 2